Online Database of Chemicals from Around the World

Glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine
[CAS# 137525-51-0]

Top Active Suppliers
Beijing Eagle Sky Pharmatech Co., Ltd. China Inquire  
+86 (10) 5979-9429
8875-5821
sophia_818@126.com
contact@eagleskypharmatech.com
QQ chat
Chemical manufacturer since 2009
chemBlink premium supplier since 2010
Identification
Classification Biochemical >> Peptide
Name Glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine
Synonyms BPC 157 trifluoroacetate salt; (4S)-4-[(2-aminoacetyl)amino]-5-[(2S)-2-[(2S)-2-[(2S)-2-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-oxopentanoic acid
Molecular Structure CAS # 137525-51-0, Glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine, BPC 157 trifluoroacetate salt, (4S)-4-[(2-aminoacetyl)amino]-5-[(2S)-2-[(2S)-2-[(2S)-2-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[2-[[(2S)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-5-oxopentanoic acid
Protein Sequence 1-15 GEPPPGKPAD DAGLV
[15-E-OH;]
Molecular Formula C62H98N16O22
Molecular Weight 1419.54
CAS Registry Number 137525-51-0
SMILES C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)NC(=O)CN
Properties
Solubility Freely soluble (990 g/L) (25 ºC), Calc.*
Density 1.366±0.06 g/cm3 (20 ºC 760 Torr), Calc.*
Index of Refraction 1.576, Calc.*
Boiling Point 1802.9±65.0 ºC (760 mmHg), Calc.*
Flash Point 1044.2±34.3 ºC, Calc.*
* Calculated using Advanced Chemistry Development (ACD/Labs) Software.
Safety Data
SDS Available
up Discovory and Applicatios
Glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine is a complex peptide composed of multiple amino acid residues. This intricate structure highlights the growing interest in peptide research, particularly in the realms of biochemistry and pharmacology. While the compound may not be widely recognized, its composition and potential applications make it a subject of exploration in various scientific fields.

The discovery of this peptide sequence stems from advances in peptide synthesis and the understanding of peptide functions in biological systems. Researchers have long studied peptides for their roles in cell signaling, enzyme regulation, and as potential therapeutics. The specific sequence of this peptide suggests that it may exhibit unique biological properties that could be harnessed for medicinal purposes.

Peptides, including this particular sequence, have garnered attention in drug discovery and development due to their high specificity and affinity for biological targets. Their structural complexity allows them to interact with a variety of receptors and enzymes, making them suitable candidates for therapeutic applications. This peptide, with its rich composition of proline and other amino acids, may influence protein folding, stability, and interactions, potentially providing insights into the design of novel therapeutic agents.

In addition to their therapeutic potential, peptides are increasingly used in research as tools for probing biological processes. This specific peptide could serve as a model compound for studying the effects of peptide structure on biological activity, offering insights into how modifications can enhance or diminish function. By exploring its interactions with various cellular targets, scientists can better understand the mechanisms underlying peptide activity and apply this knowledge to develop targeted therapies.

Furthermore, peptides like this one are being investigated for their roles in drug delivery systems. The ability of certain peptides to facilitate cellular uptake and transport makes them attractive candidates for delivering therapeutic agents directly to target cells or tissues. Researchers are exploring how this peptide can be utilized to enhance the bioavailability of drugs, particularly in challenging therapeutic areas such as cancer treatment or neurological disorders.

Despite its potential, the application of this specific peptide in clinical settings remains to be fully explored. Ongoing research is needed to investigate its stability, efficacy, and safety profile. As peptide synthesis technologies continue to advance, the opportunities for studying and utilizing complex peptide structures like this one will expand, paving the way for novel therapeutic strategies.

In summary, Glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine is a complex peptide that represents the ongoing exploration of peptide-based therapeutics and research tools. Its discovery and potential applications underscore the significance of peptides in advancing our understanding of biological processes and developing innovative therapeutic solutions.

References

1993. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology, Paris, 87(5).
DOI: 10.1016/0928-4257(93)90038-u

2019. Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation. European Journal of Pharmacology, 847.
DOI: 10.1016/j.ejphar.2019.01.030

2023. Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS. Molecules, 28(21).
DOI: 10.3390/molecules28217345
Market Analysis Reports
List of Reports Available for Glycyl-L-alpha-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-alpha-aspartyl-L-alpha-aspartyl-L-alanylglycyl-L-leucyl-L-valine
Related Products
Glycyl-L-alpha-aspartyl-L-asparaginyl-L-glutaminyl-L-isoleucyl-L-methionyl-L-prolyl-L-lysyl-L-alanylglycyl-L-leucyl-L-leucyl-L-isoleucyl-L-isoleucyl-L-valine  Glycyl-L-alpha-aspartylglycyl-L-arginyl-L-histidyl-L-alpha-aspartyl-L-leucyl-L-leucyl-L-valylglycyl-L-alanyl-L-prolyl-L-leucine  (4R)-Glycyl-4-(benzoylamino)-L-proline hydrochloride (1:1)  Glycyl-L-glutamic acid  Glycyl-L-glutamine monohydrate  Glycyl-L-glutamine monohydrate  Glycyl-L-glutaminyl-L-lysyl-L-leucyl-L-valyl-L-phenylalanyl-L-phenylalanyl-L-alanyl-L-alpha-glutamyl-L-alpha-aspartyl-L-valylglycylglycyl-6-aminohexanoyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysyl-L-lysine  Glycyl-L-glutaminyl-L-prolyl-L-arginine  Glycyl-L-glutaminyl-L-threonylglycyl-L-serylglycyl-L-lysyl-L-threonyl-L-tyrosyl-L-threonyl-L-isoleucylglycylglycylglycyl-L-histidyl-L-isoleucyl-L-alanyl-L-seryl-L-valyl-L-valine  Glycyl-L-alpha-glutamyl-L-lysylglycyl-L-asparaginyl-L-seryl-L-valyl-L-phenylalanine  Glycyl-L-a-glutamyl-L-prolyl-L-prolyl-L-prolylglycyl-L-lysyl-L-prolyl-L-alanyl-L-a-aspartyl-L-a-aspartyl-L-alanylglycyl-L-leucyl-L-valine acetate (1:1)  Glycylglycine  Glycylglycine benzyl ester tosylate  N-Glycylglycine ethyl ester hydrochloride  Glycylglycine monohydrochloride monohydrate  Glycylglycyl-L-alanine  Glycyl-glycyl-glycine  N-[N-(N-Glycylglycyl)glycyl]-glycine  Glycylglycyl-L-histidine  Glycylglycyl-L-isoleucine